The vital role of education and information in patients receiving capecitabine (Xeloda®)
- 1 January 2004
- journal article
- review article
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 8, S41-S53
- https://doi.org/10.1016/j.ejon.2004.06.008
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda®) for locally advanced and/or metastatic breast cancerHealth Technology Assessment, 2004
- Implementation of capecitabine (Xeloda®) into a cancer centre: UK experienceEuropean Journal of Oncology Nursing, 2004
- First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorinAnnals of Oncology, 2002
- Answering Patients' Needs: Oral Alternatives to Intravenous TherapyThe Oncologist, 2001
- A systematic review of the associations between dose regimens and medication complianceClinical Therapeutics, 2001
- The dynamics of change: Cancer patients' preferences for information, involvement and supportAnnals of Oncology, 1997
- Patient preferences for oral versus intravenous palliative chemotherapy.Journal of Clinical Oncology, 1997
- Measuring the quality and quantity of information-giving to in-patientsJournal of Advanced Nursing, 1996
- Information needs and sources of information for women with breast cancer: a follow‐up studyJournal of Advanced Nursing, 1996
- Information and Participation Preferences Among Cancer PatientsAnnals of Internal Medicine, 1980